GlassScriptPhysician profile
Jeff A Drasnin
NPI 1225017981
$1,624.68
in general payments reported to CMS, 2019-2025
23 companies · $133 in 2025
The $133 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $284 · 2021: $165 · 2022: $232 · 2023: $290 · 2024: $163 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $284.73 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $174.81 | 2019-2023 | Jornay Pm |
| Corium, LLC | $169.79 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $139.87 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $136.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $93.39 | 2021-2025 | Bexsero |
| Tris Pharma INC | $90.97 | 2019-2023 | Dyanavel Xr |
| Pfizer INC. | $79.34 | 2019-2024 | |
| Seqirus USA INC | $57.65 | 2021-2024 | Flucelvax Quadrivalent, Flucelvax |
| Neurelis, INC. | $56.56 | 2022-2023 | Valtoco |
| Sanofi-Aventis U.S. LLC | $41.33 | 2023-2024 | |
| Kaleo, INC. | $37.75 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $33.59 | 2022-2024 | Crysvita |
| Sobi, INC | $32.11 | 2019 | |
| Sanofi Pasteur INC. | $30.91 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $29.32 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $28.28 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $25.77 | 2021-2025 | Qelbree |
| Lnhc, INC | $19.08 | 2025 | Zelsuvmi |
| Astrazeneca Pharmaceuticals LP | $17.20 | 2023 | Flumist Quadrivalent |
| Cognoa, INC. | $16.21 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.25 | 2020 | |
| Collegium Pharmaceutical, INC. | $14.57 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Drasnin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.